Electro-Optical completes MelaFind trial
This article was originally published in Clinica
Executive Summary
Electro-Optical Sciences (EOS), of Irvington, New York, has completed its pivotal trial of MelaFind, its melanoma detection device. MelaFind was used to evaluate over 1,800 suspicious skin lesions from over 1,300 patients. All the lesions deemed "suspicious" by the system were subsequently biopsied and sent for dermatohistopathologic analysis. Results are anticipated in the fourth quarter of 2008, with a PMA application to the US FDA to follow. The noninvasive, hand-held imaging system emits multiple wavelengths of light to obtain data on suspicious pigmented skin lesions up to 2.5mm deep. It analyses these data using proprietary algorithms to compare them with a database of melanomas and benign lesions.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.